HeimEBS • NYSE
add
Emergent Biosolutions Inc
11,19 $
Eftir lokun(0,60%)-0,067
11,12 $
Lokað: 27. jan., 19:09:25 GMT-5 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
11,66 $
Dagbil
11,07 $ - 11,69 $
Árabil
1,42 $ - 15,10 $
Markaðsvirði
606,32 m. USD
Meðalmagn
1,11 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 293,80 m. | 8,61% |
Rekstrarkostnaður | 92,20 m. | -3,96% |
Nettótekjur | 114,80 m. | 143,58% |
Hagnaðarhlutfall | 39,07 | 140,12% |
Hagnaður á hvern hlut | 1,37 | — |
EBITDA | 97,70 m. | 319,31% |
Virkt skatthlutfall | 19,38% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 149,90 m. | 70,73% |
Heildareignir | 1,48 ma. | -21,94% |
Heildarskuldir | 969,40 m. | -18,94% |
Eigið fé alls | 508,40 m. | — |
Útistandandi hlutabréf | 54,18 m. | — |
Eiginfjárgengi | 1,24 | — |
Arðsemi eigna | 12,03% | — |
Ávöxtun eigin fjár | 14,71% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 114,80 m. | 143,58% |
Handbært fé frá rekstri | 153,70 m. | 156,17% |
Reiðufé frá fjárfestingum | 112,00 m. | 692,59% |
Reiðufé frá fjármögnun | -180,30 m. | -319,30% |
Breyting á handbæru fé | 85,40 m. | 10.775,00% |
Frjálst peningaflæði | 154,31 m. | 111,86% |
Um
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Framkvæmdastjóri
Stofnsett
5. sep. 1998
Höfuðstöðvar
Vefsvæði
Starfsfólk
1.600
